NCT01144949

Study of Silodosin to Facilitate Passage of Urinary Stones

A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 239 (actual)
• Sponsor: Watson Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

Conditions

• Ureteral Calculi
• Kidney Stones
• Urolithiasis

Interventions

Type	Name	Description
DRUG	silodosin	one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
DRUG	placebo	one placebo capsule orally, once daily, with food for up to 4 weeks

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2010-06-16
• Last updated: 2014-08-11
• Results posted: 2014-08-11

Locations

27 sites across 1 country: United States